Source comparison
BPC-157 NSAID Damage Gut Reversal: Full Comparison
The table below compares BPC-157 against standard pharmacological interventions for NSAID-induced gastrointestinal injury, highlighting mechanism differences and clinical application contexts. BPC-157 (200–500 mcg/day SC or oral) Angiogenesis induction, growth
This comparison does not assign a generated winner or score.
- The table below compares BPC-157 against standard pharmacological interventions for NSAID-induced gastrointestinal injury, highlighting mechanism differences and clinical application contexts.
- BPC-157 (200–500 mcg/day SC or oral)
- Angiogenesis induction, growth factor upregulation, NO pathway modulation
- 24–72 hours for initial lesion reduction; 4–8 weeks for complete healing
- High—directly promotes epithelial repair in small intestine where acid suppression has no effect
- Requires consistent multi-week dosing; not FDA-approved for human use; limited large-scale human trial data
- Most direct approach to structural repair; addresses damage PPIs cannot reach
- Proton Pump Inhibitors (omeprazole, esomeprazole 20–40 mg daily)
- Gastric acid suppression via H+/K+-ATPase inhibition
- 3–5 days for symptom relief; 4–8 weeks for gastric ulcer healing
- Low—no effect on NSAID-induced intestinal damage below the duodenum
- Does not address prostaglandin deficiency or vascular injury; rebound hyperacidity upon discontinuation
- Standard first-line for gastric ulcers but inadequate for enteropathy
- Misoprostol (200 mcg QID)
- Prostaglandin E1 analog—replaces COX-1-derived protective prostaglandins
- 2–4 weeks for ulcer prevention/healing
- Moderate—prostaglandin activity extends throughout GI tract
- High incidence of diarrhea (20–30%); requires multiple daily doses; contraindicated in pregnancy
- Effective prevention agent but poorly tolerated long-term
- Sucralfate (1 g QID)
- Forms protective gel barrier over ulcer sites; binds to positively charged proteins in damaged tissue
- 1–2 weeks for symptomatic improvement
- Low—topical effect limited to areas of direct contact; minimal systemic absorption
- Requires intact stomach acid for activation; ineffective for non-ulcer mucosal injury
- Useful adjunct for localised gastric lesions; does not drive active healing
- H2 Receptor Antagonists (ranitidine, famotidine 20–40 mg daily)
- Histamine receptor blockade—reduces gastric acid secretion
- 1–3 days for symptom relief
- Low—acid suppression only; no prostaglandin restoration or tissue repair effect
- Less potent than PPIs; no effect on intestinal injury; tachyphylaxis with chronic use
- Outdated as primary therapy for NSAID gastropathy